The ONE Study nTreg Trial (ONEnTreg13)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

November 1, 2017

Study Completion Date

November 1, 2017

Conditions
Immunosuppressive Treatment of Living-donor Renal Transplantation
Interventions
BIOLOGICAL

autologous CD4+CD25+FoxP3+ natural regulat. T cells (nTregs)

autologous CD4+CD25+FoxP3+ natural regulatory T cells (nTregs). nTregs will be infused at escalating doses of 0.5 x 10\^6, 1 x 10\^6, and 2.5-3 x 10\^6 cells/kg body weight in cohorts of three patients each.

Trial Locations (1)

13353

Charité University Medicine, Dept. of Nephrology and Internal Intensive Care, Berlin

All Listed Sponsors
lead

Prof. Dr. Petra Reinke

OTHER

NCT02371434 - The ONE Study nTreg Trial (ONEnTreg13) | Biotech Hunter | Biotech Hunter